1. An Open-Label, Multicenter, Randomized, Phase II Study of Cisplatin and Pemetrexed With or Without Cixutumumab (IMC-A12) as a First-Line Therapy in Patients With Advanced Nonsquamous Non–Small Cell Lung Cancer 
Silvia Novello, MD, PhD, Giorgio Scagliotti, MD, PhD, Gilberto de Castro, MD, PhD, Murat Kiyik, MD, Rubén Kowalyszyn, MD, MSc, Karl-Matthias Deppermann, MD, Edurne Arriola, MD, PhD, Lionel Bosquee, MD, Ruslan D. Novosiadly, MD, PhD, Tuan S. Nguyen, PhD, Amelie Forest, MSc, Shande Tang, PhD, Siva Rama Prasad Kambhampati, PhD, Jan Cosaert, MD, Martin Reck, MD, PhD 
Journal of Thoracic Oncology 
Volume 12, Issue 2, Pages (February 2017)
DOI: /j.jtho
Copyright © 2016 International Association for the Study of Lung Cancer Terms and Conditions

2. Figure 1
Study design. ECOG PS, Eastern Cooperative Oncology Group Performance Status; IGF-IR, type 1 insulin-like growth factor receptor; NSq, nonsquamous.
Journal of Thoracic Oncology  , DOI: ( /j.jtho )
Copyright © 2016 International Association for the Study of Lung Cancer Terms and Conditions

3. Figure 2
(A) Progression-free survival and (B) overall survival Kaplan-Meier curves for the cixutumumab (red) and control (blue) treatment arms in the intent-to-treat population. vs, versus; HR, hazard ratio; CI, confidence interval.
Journal of Thoracic Oncology  , DOI: ( /j.jtho )
Copyright © 2016 International Association for the Study of Lung Cancer Terms and Conditions